Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading down 29 points (-0.2%) at 16,367 as of Wednesday, March 5, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,229 issues advancing vs. 1,681 declining with 174 unchanged. The Health Care sector currently sits up 0.1% versus the S&P 500, which is unchanged. On the negative front, top decliners within the sector include XOMA ( XOMA), down 26.1%, Mylan ( MYL), down 1.9%, Biomarin Pharmaceutical ( BMRN), down 1.8%, Shire ( SHPG), down 1.4% and Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.3%. Top gainers within the sector include Boston Scientific Corporation ( BSX), up 1.1%, Express Scripts ( ESRX), up 0.9%, Regeneron Pharmaceuticals ( REGN), up 0.8%, Celgene Corporation ( CELG), up 0.7% and AbbVie ( ABBV), up 0.7%. TheStreet would like to highlight 3 stocks pushing the sector lower today: 3. Endo International ( ENDP) is one of the companies pushing the Health Care sector lower today. As of noon trading, Endo International is down $2.83 (-3.6%) to $75.15 on heavy volume. Thus far, 2.2 million shares of Endo International exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $74.71-$78.37 after having opened the day at $78.20 as compared to the previous trading day's close of $77.98. Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. Endo International has a market cap of $8.9 billion and is part of the drugs industry. Shares are up 13.9% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Endo International a buy, 1 analyst rates it a sell, and 8 rate it a hold. TheStreet Ratings rates Endo International as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Endo International Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.